Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 1, 1995
Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer
T M Behr, W S Becker, H J Bair, et al.
International Journal of Cancer
|
August 4, 1998
Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy
T M Behr, S Memtsoudis, R M Sharkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
T M Behr, B Wörmann, M Gramatzki, et al.
Cancer
|
December 24, 1997
Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry
T M Behr, R M Sharkey, G Sgouros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 1999
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters
T M Behr, G Sgouros, M G Stabin, et al.
Cancer Research
|
June 11, 1999
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model
T M Behr, M Béhé, M G Stabin, et al.
Cancer Research
|
September 1, 1995
Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives
T M Behr, R M Sharkey, M E Juweid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 1997
Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG
T M Behr, R M Sharkey, M E Juweid, et al.
Cancer Immunology, Immunotherapy : CII
|
May 1, 1997
Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22
R M Sharkey, T M Behr, M J Mattes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study
T M Behr, A L Salib, T Liersch, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 1, 1995
Comparison of complete versus fragmented technetium-99m-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer
T M Behr, W S Becker, H J Bair, et al.
International Journal of Cancer
|
August 4, 1998
Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy
T M Behr, S Memtsoudis, R M Sharkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies
T M Behr, B Wörmann, M Gramatzki, et al.
Cancer
|
December 24, 1997
Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry
T M Behr, R M Sharkey, G Sgouros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 30, 1999
Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters
T M Behr, G Sgouros, M G Stabin, et al.
Cancer Research
|
June 11, 1999
High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model
T M Behr, M Béhé, M G Stabin, et al.
Cancer Research
|
September 1, 1995
Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives
T M Behr, R M Sharkey, M E Juweid, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 1997
Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG
T M Behr, R M Sharkey, M E Juweid, et al.
Cancer Immunology, Immunotherapy : CII
|
May 1, 1997
Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22
R M Sharkey, T M Behr, M J Mattes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 1999
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study
T M Behr, A L Salib, T Liersch, et al.
Page
of 7